Dermatology
🌏 NMPANMPA news and analysis for pharmaceutical BD, investment, and market access
Access global dermatology market intelligence, drug development trends, and regulatory insights for pharma BD, investors, and analysts.
Showing 1–4 of 4 articles
Quick answer
NovaPharmaNews Dermatology hub for NMPA covers 4 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Nektar Therapeutics pipeline update: REZPEG clinical programs and regulatory context
Claruvis Pharmaceutical's Retoxin Becomes World's First Approved Recombinant Botulinum Toxin Type A in China
MorphoSys' MINJUVI (Tafasitamab) Approved in Australia for Relapsed/Refractory Follicular Lymphoma
Dayspring Pharma's CG2001 Foam Meets Primary Endpoint in Phase II Male Pattern Baldness Trial
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.